Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields With SRS and Temozolomide in Newly Diagnosed Glioblastoma
NCT04474353Phase 1Completed
- Sponsor
- Stanford University
- Start
- May 2021
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM), sponsored by Stanford University. Primary endpoint: Dose-limiting Toxicity at 5 months. Started May 2021; status: completed.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04474353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474353.